A dose range finding study of PTI-NC-733 (fixed dose combination PTI-808, PTI-428 and PTI-801)
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs PTI NC 733 (Primary) ; PTI 808
- Indications Cystic fibrosis
- Focus Adverse reactions; Proof of concept
- 04 Jul 2017 New trial record
- 29 Jun 2017 This trial is expected to begin in the end of 2017, according to a Proteostasis Therapeutics media release.
- 23 Jun 2017 According to a Proteostasis Therapeutics media release, the company expect to initiate this trial before the end of 2017.